|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
July/August 2008FeaturesCover Story Benefit Design: 10 Years, Still Shifting GearsTen years into the modern biologics era, access- and cost-management techniques still aren't refined. Why has managing biologics proven so much harder than managing other drugs? What strategies might help payers face the challenges of the future? Policy Comparative Effectiveness Research — What Path Do We Take?As existing biologics gain indications and new drugs make it to market, the array of choices makes it challenging to pick the right treatment for a given patient. Clinical effectiveness is the most important factor, but at the policy level, cost has to enter the discussion. Where? Therapeutics Late-Stage RA Therapies — the Next Generation: Strong, SpecializedThe first generation of RA biologics was good, but just the start. A new group of therapies — some novel, some familiar, but all powerful and each with a niche — will energize this market. Cost Management The Impact of Rheumatoid Arthritis and Biologics on Employers and PayersParesh Chaudhari, PharmD, MPH, frames the business case for employers to look beyond the direct medical costs of treatment of RA and consider employee health benefits as an investment. Q&A Stem Cells: Health Insurance You Can Bank OnRobin Smith, MD, MBA, isn’t claiming she has found the fountain of youth, but she is certain her company, NeoStem, can help prevent many costly, debilitating scourges of older age. DepartmentsOpeners Olympian FeatsOlympian feats, cover to cover. Editorial Point With Pride, View With Alarm, End With HopeOf pride, alarm, and hope. Drug Track Research, Conferences, and FDA ActionsApprovals, research, and conference coverage. Health Plan Confidential Is There a Better Way To Guide Payers On Off-Label Coverage?Better guidance for off-label coverage? At a Glance Rheumatoid Arthritis: Prevalence, Economics, and Implications for Payers and PurchasersPrevalence of disease, economics of care, and implications for payers, as told in charts. Specialty Pharmacy The Evolution of Specialty PharmacyThe evolution of SP and where it’s heading. Employer to Employer Under the Hood: GM’s Strategy for Making Biologics AccessibleGM’s challenges in managing biologics. Personalized Medicine Declaring War on Warfarin MisdosingDeclaring war on warfarin misdosing. Trends Growth of Specialty Drug Utilization Slows Over 4 YearsSpecialty drug utilization growth slows. |
|||||